R Michael Tuttle

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout
    R Michael Tuttle
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Thyroid 18:839-46. 2008
  2. ncbi Postoperative management of differentiated thyroid cancer
    Erik G Cohen
    Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Otolaryngol Clin North Am 36:129-57. 2003
  3. ncbi Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
    Richard J Robbins
    Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:498-505. 2006
  4. ncbi Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients
    E Robenshtok
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 97:2706-13. 2012
  5. ncbi Challenging cases in thyroid cancer: a multidisciplinary approach
    Michael Tuttle
    Endocrine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Nucl Med Mol Imaging 31:605-12. 2004
  6. ncbi Follow up approaches in thyroid cancer: a risk adapted paradigm
    R Michael Tuttle
    Department of Medicine, Joan and Sanford I Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Endocrinol Metab Clin North Am 37:419-35, ix-x. 2008
  7. ncbi Radioactive iodine therapy in poorly differentiated thyroid cancer
    R Michael Tuttle
    Department of Radiology, Memorial Hospital, Weill Medical College of Cornell University New York, NY, USA
    Nat Clin Pract Oncol 4:665-8. 2007
  8. ncbi Papillary thyroid cancer: monitoring and therapy
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, and Memorial Sloan Kettering Cancer Center, Zuckerman Building, Room 834, 1275 York Avenue, New York, NY 10021, USA
    Endocrinol Metab Clin North Am 36:753-78, vii. 2007
  9. ncbi Investigational therapies for metastatic thyroid carcinoma
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:641-6. 2007
  10. ncbi Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors
    Rebecca Leboeuf
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Thyroid 17:543-7. 2007

Detail Information

Publications75

  1. ncbi ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout
    R Michael Tuttle
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Thyroid 18:839-46. 2008
    ....
  2. ncbi Postoperative management of differentiated thyroid cancer
    Erik G Cohen
    Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Otolaryngol Clin North Am 36:129-57. 2003
    ..Functional radionuclide imaging, such as FDG PET, now allows us to localize recurrent disease in patients with elevated serum thyroglobulin but negative 131I scan...
  3. ncbi Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
    Richard J Robbins
    Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Endocrinol Metab 91:498-505. 2006
    ..We hypothesized that the metabolic activity of metastatic lesions, as defined by retention of 2-[(18)F]fluoro-2-deoxyglucose (FDG), would correlate with prognosis...
  4. ncbi Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients
    E Robenshtok
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 97:2706-13. 2012
    ..The risk of loco-regional recurrence in papillary thyroid cancer (PTC) patients ranges from 15-30%. However, the clinical significance of small-volume loco-regional recurrence detected by highly sensitive ultrasonography is unclear...
  5. ncbi Challenging cases in thyroid cancer: a multidisciplinary approach
    Michael Tuttle
    Endocrine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Nucl Med Mol Imaging 31:605-12. 2004
    ....
  6. ncbi Follow up approaches in thyroid cancer: a risk adapted paradigm
    R Michael Tuttle
    Department of Medicine, Joan and Sanford I Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Endocrinol Metab Clin North Am 37:419-35, ix-x. 2008
    ....
  7. ncbi Radioactive iodine therapy in poorly differentiated thyroid cancer
    R Michael Tuttle
    Department of Radiology, Memorial Hospital, Weill Medical College of Cornell University New York, NY, USA
    Nat Clin Pract Oncol 4:665-8. 2007
    ..He developed an early cervical recurrence that was treated with modified neck dissection. He subsequently developed biopsy-proven progressive pulmonary metastases...
  8. ncbi Papillary thyroid cancer: monitoring and therapy
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, and Memorial Sloan Kettering Cancer Center, Zuckerman Building, Room 834, 1275 York Avenue, New York, NY 10021, USA
    Endocrinol Metab Clin North Am 36:753-78, vii. 2007
    ..In this article, the authors compare and contrast the recommendations from the various guidelines in an attempt to define areas of consensus and explore possible reasons for differing recommendations...
  9. ncbi Investigational therapies for metastatic thyroid carcinoma
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 5:641-6. 2007
    ..Given the dramatic increase in availability of thyroid cancer clinical trials, all patients with radioactive iodine-refractory, progressive metastatic thyroid cancer should be considered for inclusion in a novel therapy trial...
  10. ncbi Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors
    Rebecca Leboeuf
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Thyroid 17:543-7. 2007
    ..Since pregnancy can stimulate thyroid growth, we examined the effect of pregnancy on recurrence and serum thyroglobulin (Tg) shortly after delivery in thyroid cancer survivors...
  11. ncbi Medical management of thyroid cancer: a risk adapted approach
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University, New York, New York 10021, USA
    J Surg Oncol 97:712-6. 2008
    ....
  12. ncbi Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer
    R Michael Tuttle
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 47:1587-91. 2006
    ....
  13. ncbi A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer
    R Michael Tuttle
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Control 18:89-95. 2011
    ....
  14. ncbi Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function
    R Michael Tuttle
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 20:257-63. 2010
    ....
  15. ncbi Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association st
    R Michael Tuttle
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 20:1341-9. 2010
    ....
  16. ncbi Clinical presentation and clinical outcomes in Chernobyl-related paediatric thyroid cancers: what do we know now? What can we expect in the future?
    R M Tuttle
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Oncol (R Coll Radiol) 23:268-75. 2011
    ....
  17. ncbi Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 89:6010-6. 2004
    ..We conclude that the location and volume of metastases influence basal Tg, but not its responsiveness to rhTSH, whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH...
  18. ncbi Incidence and significance of Delphian node metastasis in papillary thyroid cancer
    N Gopalakrishna Iyer
    Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York 10065, USA
    Ann Surg 253:988-91. 2011
    ..The objective of this study was to determine the incidence and significance of Delphian node (DN) metastasis in papillary thyroid cancer...
  19. ncbi Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension
    Julio Ricarte-Filho
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Thyroid 22:575-84. 2012
    ..The objective of this study is to assess the value of meticulous histopathologic examination and genotyping in stratifying these patients into clinically relevant prognostic subgroups...
  20. ncbi Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal
    R Michael Tuttle
    Division of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 49:764-70. 2008
    ..However, no published study has determined the effectiveness of rhTSH preparations on the important endpoint of disease recurrence...
  21. ncbi Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma
    Michael Rivera
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:48-56. 2008
    ..However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date...
  22. ncbi The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer
    Ravinder K Grewal
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Nucl Med 51:1361-7. 2010
    ..We performed planar imaging and SPECT/CT in a consecutive series of patients after (131)I therapy...
  23. ncbi Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity
    Volkert B Wreesmann
    Laboratory of Epithelial Cancer Biology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Genes Chromosomes Cancer 40:355-64. 2004
    ..Our findings suggest a stronger relationship between the FVPTC and FTA/FTC than previously appreciated and support further consideration of the current classification of thyroid neoplasms...
  24. ncbi Disease-related death in patients who were considered free of macroscopic disease after initial treatment of well-differentiated thyroid carcinoma
    Iain J Nixon
    Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 21:501-4. 2011
    ..3%). In contrast to earlier reports, death caused by central compartment disease in this recent series is very rare, with metastatic disease accounting for almost all fatalities...
  25. ncbi Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications
    Ronald A Ghossein
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 17:655-61. 2007
    ..To assess the biologic and clinical behavior of TCV without ETE, we performed a detailed comparative clinicopathologic analysis of classical PTC and TCV without ETE...
  26. ncbi Micromedullary thyroid cancer: how micro is truly micro?
    Venu G Pillarisetty
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 16:2875-81. 2009
    ..The aggressive nature of medullary thyroid cancer (MTC) is evidenced by its propensity to present early with lymph node (LN) metastases. The clinical significance of sporadic MTC < or =1 cm (micro-MTC) is not clearly defined...
  27. ncbi A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 43:1482-8. 2002
    ..During this same time period, other patients at our center were prepared for RRA by hormone withdrawal...
  28. ncbi Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy
    N Gopalakrishna Iyer
    Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 117:4439-46. 2011
    ..The objective of this study was to evaluate patterns of RAI use and elevated risk of secondary primary malignancies (SPM) in patients with low-risk (T1N0) WDTC...
  29. ncbi Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern)
    Michael Rivera
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Thyroid 19:119-27. 2009
    ..This study aims to assess the behavior of EPTC according to its growth pattern...
  30. ncbi Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients
    David Hiltzik
    Department of Otolaryngology-Head and Neck Surgery, Columbia University, New York, NY, USA
    Cancer 106:1286-95. 2006
    ..RAI uptake occurs in a significant number of patients with PDTC...
  31. ncbi Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity
    Jeffrey Liu
    Department of Otolaryngology-Head and Neck Surgery, Columbia University, New York, New York, USA
    Cancer 107:1255-64. 2006
    ..If the current findings are confirmed, then strong consideration should be given to reclassifying encapsulated FVPTC as an entity that is close to the FTA/FTC class of tumors...
  32. ncbi Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels
    Seng C Ong
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 48:501-7. 2007
    ..The role of (18)F-FDG PET in MTC remains somewhat unclear. We reviewed our own experience with (18)F-FDG PET in postthyroidectomy MTC patients with elevated calcitonin...
  33. ncbi Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation
    Ravinder K Grewal
    Division of Nuclear Medicine, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 50:1605-10. 2009
    ..However, the incidence, time course, and ultimate resolution of SSEs that develop in the first few months after a single administered activity of RAI for remnant ablation has not be adequately defined...
  34. ncbi Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?
    Richard J Robbins
    Endocrinology Service, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Endocrinol Metab 87:3242-7. 2002
    ..We conclude that the stimulated Tg alone is not sufficient by itself to screen unselected patients, but that it may be sufficient in low risk patients, especially those who have had a prior negative DxWBS...
  35. ncbi The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland
    Iain J Nixon
    Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer, 1275 York Ave, New York, NY 10065, USA
    Thyroid 22:884-9. 2012
    ..The objective of this study was to report outcomes for patients presenting with distant metastases managed by thyroidectomy and radioactive iodine (RAI) therapy...
  36. ncbi Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression
    Genevieve Rondeau
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Thyroid 21:845-53. 2011
    ....
  37. ncbi Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing-related increases in body mass in thyroid cancer survivors
    Hanah N Polotsky
    Department of Medicine, Memorial Sloan Kettering Cancer, New York, NY, USA
    Clin Endocrinol (Oxf) 76:582-5. 2012
    ....
  38. ncbi Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer
    Benjamin D Rosenbluth
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 63:1419-26. 2005
    ..Ideal planning target volume doses have yet to be determined. Additional patients and long-term follow-up are needed to confirm these preliminary findings and to clarify late toxicities...
  39. ncbi Genome-wide appraisal of thyroid cancer progression
    Volkert B Wreesmann
    Laboratory of Epithelial Cancer Biology, Head and Neck Service, New York, New York 10021, USA
    Am J Pathol 161:1549-56. 2002
    ..Our data suggests that the development of chromosomal instability underlies the progression to more aggressive phenotypes of thyroid cancer and sheds light on the possible genomic aberrations that may be selected for during this process...
  40. ncbi Medullary thyroid carcinoma: ethical issues for the surgeon
    Andrew G Shuman
    Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 19:2102-7. 2012
    ..We provide an overview of the ethical issues facing surgeons caring for patients with familial medullary thyroid carcinoma, and recommend interventions and resources to assist in decision making in these difficult situations...
  41. ncbi Skeletal-related events due to bone metastases from differentiated thyroid cancer
    Azeez Farooki
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Clin Endocrinol Metab 97:2433-9. 2012
    ..The risk and rate of SRE after diagnosis of bone metastasis have not been described in thyroid cancer; antiresorptive agents are not routinely used...
  42. ncbi Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1
    Julio C Ricarte-Filho
    Human Oncology and Pathogenesis Program and Departments of Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:4885-93. 2009
    ....
  43. ncbi Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members
    Ashok R Shaha
    Department of Surgery, Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Laryngoscope 116:1704-7. 2006
    ..However, its indications in adults remain unclear at this time...
  44. ncbi Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival
    Luc G T Morris
    Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 20:153-8. 2010
    ..Our objective was to utilize a large cancer registry to obtain sufficient power to differentiate between outcomes in cases of TCV and PTC...
  45. ncbi Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans
    Mona M Sabra
    Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Thyroid 22:877-83. 2012
    ....
  46. ncbi Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence
    Jonathan Hugo
    Endocrinology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Thyroid 22:1007-15. 2012
    ..The goal of this study was to examine clinical outcomes after rhTSH stimulated RRA in a larger cohort of thyroid cancer patients at higher risk of recurrence and disease-specific mortality...
  47. ncbi The Japanese tsunami and resulting nuclear emergency at the Fukushima Daiichi power facility: technical, radiologic, and response perspectives
    Lawrence T Dauer
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 52:1423-32. 2011
    ..The situation at the Fukushima Daiichi nuclear facility remains fluid, and the long-term environmental and health impact will likely take years to fully delineate...
  48. ncbi Evaluation of adult papillary thyroid carcinomas by comparative genomic hybridization and microsatellite instability analysis
    Andrew J Bauer
    Department of Pediatrics, Walter Reed Army Medical Center, USA, Washington, DC, USA
    Cancer Genet Cytogenet 135:182-6. 2002
    ..026). We conclude that although chromosomal and microsatellite instability are uncommon in PTC, tumors with chromosomal aberrations are more likely to be associated with invasion...
  49. ncbi Similarities and differences in follicular cell-derived thyroid cancer management guidelines used in Europe and the United States
    Genevieve Rondeau
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Nucl Med 41:89-95. 2011
    ..Furthermore, follow up and additional therapeutic recommendations are based on revised risk estimates that reflect an individual patient's response to therapy...
  50. ncbi Risk-adapted management of thyroid cancer
    R Michael Tuttle
    Joan and Sanford I Weill Medical College of Cornell University and Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Endocr Pract 14:764-74. 2008
    ..To describe a risk-adapted management paradigm for patients with differentiated thyroid cancer...
  51. ncbi Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH
    H Tala
    Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Endocrinol Metab 96:2105-11. 2011
    ..Elevated levels of TSH markedly enhance the effectiveness of radioiodine (RAI) therapy in metastatic thyroid cancer...
  52. ncbi Papillary microcarcinoma of the thyroid
    Ashok R Shaha
    J Surg Oncol 95:532-3. 2007
  53. ncbi Microarray comparative genomic hybridization reveals genome-wide patterns of DNA gains and losses in post-Chernobyl thyroid cancer
    Robert R Kimmel
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Radiat Res 166:519-31. 2006
    ..2, 16q21-q12.2, 17q25.1, 19p13.31-qter, 22q11.21 and 22q13.2. Copy number changes, particularly gains, in post-Chernobyl thyroid cancer are influenced by radiation exposure and age at exposure, in addition to the neoplastic process...
  54. ncbi Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents
    Aneeta Patel
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Pediatr Res 52:737-44. 2002
    ..06). We conclude that NIS expression is associated with a lower risk of recurrence for PTC and FTC of children and adolescents...
  55. ncbi Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes
    Ann M Straight
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer Chemother Pharmacol 57:7-14. 2006
    ..The demonstrated molecular impact against angiogenic related genes specifically supports future strategies combining APLD with VEGF interacting agents...
  56. ncbi Papillary and follicular thyroid cancers in children
    Vasyl Vasko
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Endocr Dev 10:140-72. 2007
    ..We have divided this chapter into two major sections, the first of which pertains to thyroid nodules and the second to well-differentiated thyroid cancers including papillary, follicular and other variants...
  57. ncbi Thyroid cancers express CD-40 and CD-40 ligand: cancers that express CD-40 ligand may have a greater risk of recurrence in young patients
    Amy Costello
    Department of Pediatrics, Wright Patterson Air Force Medical Center, Dayton, Ohio, USA
    Thyroid 15:105-13. 2005
    ..03). We conclude that the majority of thyroid cancers express CD-40 and CD-40 ligand. In patients < or =21 years of age, tumors with intense expression of CD-40 ligand are more often multifocal, aggressive, and recurrent...
  58. ncbi Treatment of thyroid cancer: 2007--a basic review
    Gregory W Randolph
    Thyroid and Parathyroid Surgical Divisions, Massachusetts Eye and Ear Infirmary, Endocrine Surgical Service, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 69:S92-7. 2007
  59. ncbi BRAF mutations are uncommon in papillary thyroid cancer of young patients
    Karen Penko
    Department of Pediatrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Thyroid 15:320-5. 2005
    ..We conclude that BRAF mutations are less common in PTC from young patients, and ret/PTC rearrangements were the most common mutation found in these childhood PTC...
  60. ncbi Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood
    Siegal Sadetzki
    The Cancer Epidemiology Unit, Gertner Institute, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    J Clin Endocrinol Metab 89:2281-9. 2004
    ....
  61. ncbi The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents
    Patricia A Powers
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    J Pediatr Endocrinol Metab 17:339-43. 2004
    ..0005). A cutoff score of 4.0 provides a PPV of 29% and NPV of 94% in predicting recurrence, and a PPV of 43% and NPV of 91% in predicting persistent disease. MACIS scores may be useful in predicting outcome in the pediatric population...
  62. ncbi Tumor size and extent of disease at diagnosis predict the response to initial therapy for papillary thyroid carcinoma in children and adolescents
    Patricia A Powers
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC 20307, USA
    J Pediatr Endocrinol Metab 16:693-702. 2003
    ..022) and dose (p = 0.002) required to achieve first remission. We conclude that extensive disease at diagnosis and larger tumor size predict failure to remit after initial treatment of PTC in children and adolescents...
  63. ncbi Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes
    Jitu Modi
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Clin Endocrinol Metab 88:4418-25. 2003
    ..We conclude that the immune response against PTC is important and also complex, involving more than one type of lymphocyte...
  64. ncbi Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive
    Harkirtin Gydee
    Department of Pediatrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    Pediatr Res 55:709-15. 2004
    ..Tumors that express IGF-I-R are more likely to show aggressive clinical features (invasion beyond the capsule, metastasis, or recurrence) and persistence despite treatment...
  65. ncbi Treatment of recurrent papillary thyroid carcinoma in children and adolescents
    Patricia A Powers
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    J Pediatr Endocrinol Metab 16:1033-40. 2003
    ..There were no deaths. In conclusion, although we had only one child less than 10 years of age in our study, these and previous data suggest that treatment of recurrent PTC in children is generally effective...
  66. ncbi Autoimmune thyroid disease associated with environmental thyroidal irradiation
    Christie R Eheman
    Epidemiology and Health Services Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Thyroid 13:453-64. 2003
    ..The results of these studies will be important in determining the appropriate clinical follow-up of persons exposed to environmental thyroidal irradiation...
  67. ncbi Management guidelines for patients with thyroid nodules and differentiated thyroid cancer
    David S Cooper
    Sinai Hospital of Baltimore and Johns Hopkins University School of Medicine, MD, USA
    Thyroid 16:109-42. 2006
  68. ncbi Thyroid carcinoma
    Steven I Sherman
    The University of Texas M.D. Anderson Cancer Center, USA
    J Natl Compr Canc Netw 5:568-621. 2007
  69. ncbi Consensus Statement #1: Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society
    Hossein Gharib
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Thyroid 15:24-8; response 32-3. 2005
  70. ncbi Cytoplasmic localization of the paired box gene, Pax-8, is found in pediatric thyroid cancer and may be associated with a greater risk of recurrence
    William T Scouten
    Department of Pediatrics, Uniformed Services School of the Health Sciences, Bethesda, Maryland 20814, USA
    Thyroid 14:1037-46. 2004
    ....
  71. ncbi Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults
    Aneeta Patel
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Cancer Chemother Pharmacol 53:409-14. 2004
    ..The results support the hypothesis that capecitabine is activated in the majority of differentiated thyroid cancers and that 32% have favorable expression of all three enzymes (TP, TS, and DPD)...
  72. ncbi Erythropoietin and the erythropoietin receptor are expressed by papillary thyroid carcinoma from children and adolescents. Expression of erythropoietin receptor might be a favorable prognostic indicator
    Thomas G Eccles
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Ann Clin Lab Sci 33:411-22. 2003
    ..3 +/- 0.7, p = 0.004; recurrence = 3/6, p = 0.029). We conclude that the majority of PTC from children and adolescents express EPO-R, a finding associated with favorable prognostic indicators and a lower risk of recurrence...
  73. ncbi Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model
    Andrew J Bauer
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
    Ann Clin Lab Sci 33:192-9. 2003
    ..Animal weight was similar in both groups (29.1 +/- 1.1 vs 27.4 +/- 1.1 g, p = 0.30). In conclusion, systemic VEGF-MAb significantly reduced the growth of PTC, suggesting that VEGF-MAb might be useful for treatment of resistant PTC...
  74. ncbi Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice
    Andrew J Bauer
    Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Thyroid 12:953-61. 2002
    ..Thalidomide has no effect on tumor growth, but is also associated with increased VEGF and p53 expression. These observations provide the first evidence that VEGF-mAb-induced angiogenesis blockade may be of use for the treatment of ATC...
  75. ncbi Intense expression of the b7-2 antigen presentation coactivator is an unfavorable prognostic indicator for differentiated thyroid carcinoma of children and adolescents
    Rima Shah
    Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Clin Endocrinol Metab 87:4391-7. 2002
    ..04). In conclusion, these data support the hypothesis that the antigen presentation coactivators B7-1 and B7-2 may be important for lymphocytic infiltration and the immune response against thyroid carcinoma...